Schroder Investment Management Group
RPRX icon

Schroder Investment Management Group’s Royalty Pharma RPRX Stock Holding History

Schroder Investment Management Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4M Buy
381,583
+117,670
+45% +$6.12M 0.02% 537
2026
Q1 		$12.7M Sell
263,913
-145,744
-36% -$6.38M 0.01% 609
2025
Q4 		$15.8M Buy
409,657
+97,301
+31% +$3.71M 0.01% 562
2025
Q3 		$11M Buy
312,356
+86,842
+39% +$3.14M 0.01% 649
2025
Q2 		$8.13M Buy
225,514
+127,449
+130% +$4.22M 0.01% 677
2025
Q1 		$3.05M Sell
98,065
-98,294
-50% -$3.12M ﹤0.01% 851
2024
Q4 		$5.01M Sell
196,359
-354,483
-64% -$9.4M ﹤0.01% 769
2024
Q3 		$15.6M Buy
550,842
+2,582
+0.5% +$71.5K 0.02% 586
2024
Q2 		$14.5M Sell
548,260
-4,938
-0.9% -$137K 0.02% 556
2024
Q1 		$16.8M Buy
553,198
+451,942
+446% +$13.3M 0.02% 536
2023
Q4 		$2.84M Buy
101,256
+88,678
+705% +$2.44M ﹤0.01% 861
2023
Q3 		$341K Sell
12,578
-219,241
-95% -$6.51M ﹤0.01% 1136
2023
Q2 		$7.13M Buy
231,819
+2,924
+1% +$99K 0.01% 709
2023
Q1 		$8.25M Sell
228,895
-319
-0.1% -$11.8K 0.01% 669
2022
Q4 		$9.06M Buy
229,214
+14,553
+7% +$607K 0.01% 653
2022
Q3 		$8.63M Sell
214,661
-16,293
-7% -$696K 0.01% 646
2022
Q2 		$9.72M Buy
230,954
+36,105
+19% +$1.48M 0.01% 658
2022
Q1 		$7.6M Buy
194,849
+27,517
+16% +$1.08M 0.01% 731
2021
Q4 		$6.67M Buy
167,332
+23,802
+17% +$925K 0.01% 689
2021
Q3 		$5.19M Sell
143,530
-1,398
-1% -$54.3K 0.01% 781
2021
Q2 		$5.94M Buy
144,928
+2,894
+2% +$123K 0.01% 796
2021
Q1 		$6.2M Buy
142,034
+19,752
+16% +$936K 0.01% 771
2020
Q4 		$6.12M Sell
122,282
-1,887
-2% -$80.1K 0.01% 757
2020
Q3 		$5.27M Buy
124,169
+26,563
+27% +$1.14M 0.01% 715
2020
Q2 		$4.74M Buy
+97,606
New +$4.83M 0.01% 684

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schroder Investment Management Group's RPRX Position: Q2 2026 in Review

Schroder Investment Management Group increased its Royalty Pharma (RPRX) stake by 45% in Q2 2026, buying an estimated $6.12M and bringing the position to 381,583 shares worth $21.4M. The position accounts for 0.02% of the portfolio, ranked #537.

Schroder Investment Management Group first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Schroder Investment Management Group held 381,583 shares of Royalty Pharma worth $21.4M as of Q2 2026.
  • Schroder Investment Management Group bought 117,670 Royalty Pharma shares in Q2 2026, an estimated $6.12M.
  • Royalty Pharma made up 0.02% of Schroder Investment Management Group's portfolio in Q2 2026, its #537 holding.
  • Schroder Investment Management Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.